VCM
DYN icon

Versant Capital Management’s Dyne Therapeutics DYN Stock Holding History

Versant Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.1K Hold
859
– – ﹤0.01% 1951
2026
Q1 		$15.6K Hold
859
– – ﹤0.01% 1938
2025
Q4 		$16.8K Hold
859
– – ﹤0.01% 1743
2025
Q3 		$10.9K Buy
859
+815
+1,852% +$9.29K ﹤0.01% 1904
2025
Q2 		$419 Sell
44
-239
-84% -$2.63K ﹤0.01% 2559
2025
Q1 		$2.96K Buy
+283
New +$4.05K ﹤0.01% 2206

Other funds holding DYN

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
AP
Aspect Partners Fairfax, Virginia $268M AUM 22.57% 1-Year Est. Return
AFC
Ares Financial Consulting Calabasas, California $139M AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Versant Capital Management's DYN Position: Q2 2026 in Review

Versant Capital Management held its Dyne Therapeutics (DYN) position steady in Q2 2026 at 859 shares worth $19.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1951.

Versant Capital Management first reported a position in DYN in Q1 2025 and has held it in 6 quarters since. 12 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Versant Capital Management held 859 shares of Dyne Therapeutics worth $19.1K as of Q2 2026.
  • Versant Capital Management left its Dyne Therapeutics share count unchanged in Q2 2026.
  • Dyne Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1951 holding.
  • Versant Capital Management first reported a position in Dyne Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 12 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.